Adam Lloyd
Adam Lloyd is a Field Service Engineer at Synnovis & SYNLAB in London, with a background in Biomedical Science and laboratory operations. He started his career working in Blood Sciences as a Biomedical Scientist gaining firsthand experience in clinical chemistry and routine laboratory work.
After progressing into specialist and senior roles, Adam led in the setup and verification of seven Synnovis laboratory sites including the Synnovis Hub in Central London. This involved the implementation of Abbott Alinity analysers and GLP track systems. As a Senior Biomedical Scientist and Production Lead, he supported day-to-day running of clinical chemistry services, helped improve workflows and functioned as a point of contact for analyser and automation issues across different sites. He also set up company user groups in hopes this can be taken across all of Synlab UK&I. Recently finishing his master’s degree where the final focus looked at testing of Ammonia on Abbott Alinity analysers.
In March 2026, Adam moved into his current role as an in-house Field Service Engineer, supporting laboratory instrumentation within a multi-site hub environment. His role includes installation, validation, maintenance, and troubleshooting of diagnostic equipment.
Hyperammonaemia and ammonia assays
This presentation evaluates the performance of commonly used ammonia assays, highlighting how assay design influences result accuracy in hyperammonaemia patients. Single stage, rate-based assays offer rapid turnaround times, but lack a sample blank correction step and are therefore susceptible to clinically significant interference from high ALT, haemolysis, icterus, and lipaemia, which are often present during metabolic decompensation and acute liver injury. Patient comparison and interference studies demonstrated that these interferences could lead to substantial positive bias, risking misinterpretation of ammonia severity.
In contrast, two reagent assays incorporating a blank correction step showed greater analytical resilience, particularly in patients with markedly elevated liver enzymes.
The work illustrates that assay speed alone does not equate to clinical safety. Selection of ammonia assays must prioritise robustness to interference and consistent performance in critically unwell patients to support safe, 24/7 metabolic and hepatology services.
Managed and payment processed by:
KC Jones conference&events Ltd
Telephone: +44 (0)1332 947072
Email: bimdg@kc-jones.co.uk